Global Anesthesia Drug Market: Key Developments
In April 2022, GE Healthcare, a U.S.-based multinational healthcare and medical technology company, received the U.S. Food and Drugs Approval (FDA) pre-market approval (PMA) for its End-tidal (Et) control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System. The device is to have a direct control of the end-tidal concentration that reflects the drug level in the patient’s blood along with that low-flow anesthesia has benefits for hospitals and the environment.
In September 2021, Medical University of Vienna had positive results from Phase IV for ADV6209 which is a new oral Midazolam formulation, on preoperative anxiety and sedation levels in paediatric anaesthesia.
In May 2021, Heron Therapeutics, Inc., a multinational biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for ZYNRELEF, which is indicated in adults for soft tissue to produce postsurgical analgesia for up to 72 hours after small-to-medium open abdominal, foot and ankle, and lower extremity total joint arthroplasty surgical procedures.
General Anesthesia Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients